跳至主要内容
临床试验/NCT03728348
NCT03728348已完成不适用

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

Exact Sciences Corporation39 个研究点 分布在 1 个国家目标入组 983 人开始时间: 2018年11月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
983
试验地点
39
主要终点
Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49

研究概览

简要总结

The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.

详细描述

Subjects aged 45-49 at average risk for development of CRC will be enrolled. Subjects will complete the mt-sDNA screening test (Cologuard) followed by completion of a screening colonoscopy. The results of the mt-sDNA screening test (Cologuard) will not be provided to investigators for clinical management of study subjects. Personnel performing the colonoscopy and producing the resulting report and personnel performing histopathological review of tissue (if applicable) will remain blinded to the results of the mt-sDNA screening test (Cologuard) result.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
45 Years 至 49 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must meet the following criteria to be eligible for the study:
  • Subject is at average risk for development of CRC.
  • Subject is able and willing to undergo a screening colonoscopy.
  • Subject is ≥ 45 and ≤ 49 years of age at the time of enrollment.
  • Subject is willing and able to sign informed consent.
  • Subject is able and willing to provide stool sample(s) according to written instructions provided.

排除标准

  • Subject has a history of CRC or adenoma.
  • Subject has ≥2 first-degree relatives who have been diagnosed with CRC
  • Subject has one first-degree relative with CRC diagnosed before the age of
  • Subject has any of the following: Overt rectal bleeding, e.g., hematochezia or melena within the previous 30 days (blood on toilet paper, after wiping, does not constitute rectal bleeding). Positive fecal occult blood test or FIT within the previous six (6) months. Subject has had a previous colonoscopy. Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
  • Subject has a diagnosis or personal history of any of the following conditions, including: Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome). Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome").Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis.
  • Subject has a family history of: Familial adenomatous polyposis (also referred to as "FAP"), Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
  • Subjects with Cronkhite-Canada Syndrome.
  • Subject has a diagnosis of inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
  • Subject has a history of aerodigestive tract cancer.
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
  • Subject has any condition that in the opinion of the investigator should preclude participation in the study.

结局指标

主要结局

Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49

时间窗: Through study completion, an average of 60 days

An optical colonoscopic procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. Tests were processed independently of colonoscopic findings. The test functions as a screening tool by generating a score, based on the detection of hemoglobin and multiple DNA methylation and mutational markers, together with an assessment of the total amount of human DNA in each sample. Specificity =100\*(multi-target stool DNA test negative/negative colonoscopy)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (39)

Loading locations...

相似试验